Omission of Surgery in Clinically Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Complete Response Following Standard Anti-HER2-based Neoadjuvant Therapy

Stopped The study was prematurely halted primarily due to low patient accrual. Despite efforts to optimize recruitment, the enrollment rate remained insufficient to meet the predefined targets, and continuation was deemed unfeasible

Conditions

• HER2-positive Breast Cancer
• Stage I Breast Cancer

Interventions

• BIOLOGICAL: Trastuzumab and pertuzumab Subcutaneous Fixed-Dose Combination

Sponsor

Fundacio Clinic Barcelona

Collaborators

• [object Object]
• [object Object]